Background The benefit/risk ratio of stenting in acute ST-segment elevation myocardial infarction （STEMI） patients with single vessel intermediate stenosis culprit lesions merits further study, therefore the subject...Background The benefit/risk ratio of stenting in acute ST-segment elevation myocardial infarction （STEMI） patients with single vessel intermediate stenosis culprit lesions merits further study, therefore the subject of the present study. Methods and results It was a pro- spective, multicenter, randomized controlled trial. Between April 2012 and July 2015, 399 acute STEMI patients with single vessel disease and intermediate （40%-70%） stenosis of the culprit lesion before or after aspiration thrombectomy and/or intracoronary tirofiban （15 pg/kg） were enrolled and were randomly assigned （h 1） to stenting group （n = 201） and non-stenting group （n = 198）. In stenting group, patients received pharmacologic therapy plus standard percutaneous coronary intervention （PCI） with stent implantation. In non-stenting group, pa- tients received pharmacologic therapy and PCI （thrombectomy）, but without dilatation or stenting. Primary endpoint was 12-month rate of major adverse cardiac and eerebrovascular events （MACCE）, a composite of cardiac death, non-fatal myocardial infarction （M1）, repeat re- vascularization and stroke. Secondary endpoints were 12-month rates of all cause death, ischemia driven admission and bleeding complica- tion. Median follow-up time was 12.4 ~ 3.1 months. At 12 months, MACCE occurred in 8.0% of the patients in stenting group, as compared with 15.2% in the non-stenting group （adjusted HR： 0.42, 95% Ch 0.19-0.89, P = 0.02）. The stenting group had lower non-fatal MI rate than non-stenting group, （1.5% vs. 5.5%, P = 0.03）. The two groups shared similar cardiac death, repeat revascularization, stroke, all cause death, ischemia driven readmission and bleeding rates at 12 months. Conclusions Stent implantation had better efficacy and safety in reducing MACCE risks among acute STEMI patients with single vessel intermediate stenosis culprit lesions.展开更多
目的对人A组轮状病毒进行检测及分离鉴定,并研究其各基因片段的遗传进化关系。方法2019-2020年对湖北武汉市和襄阳市临床腹泻病人的粪便样品进行采集,共319份。设计特异性轮状病毒VP6基因引物,RT-PCR检测轮状病毒的感染情况。将阳性样...目的对人A组轮状病毒进行检测及分离鉴定,并研究其各基因片段的遗传进化关系。方法2019-2020年对湖北武汉市和襄阳市临床腹泻病人的粪便样品进行采集,共319份。设计特异性轮状病毒VP6基因引物,RT-PCR检测轮状病毒的感染情况。将阳性样品接种于MA104细胞进行轮状病毒的分离。RT-PCR特异性扩增VP6基因和特异性间接免疫荧光对其进行病毒鉴定及病毒增殖检测;并进一步通过RT-PCR扩增轮状病毒的11个基因片段,在线工具Rota C V2.0对测序结果进行分型分析。Mega软件对其全基因组序列进行遗传进化分析。结果轮状病毒感染阳性标本共69份,阳性率为21.63%。成功分离获得11株人轮状病毒,主要衣壳蛋白VP7和VP4基因型均为G9P[8]型。其中3株轮状病毒归属于类Wa株毒株,基因型图谱为G9-P[8]-I1-R1-C1-M1-A1-N1-T1-E1-H1。8株毒株在Wa-like的基因型中具有DS-1-like的NSP4为E2基因型特征。基因型图谱为G9-P[8]-I1-R1-C1-M1-A1-N1-T1-E2-H1。结论G9P[8]型人轮状病毒毒株在2019-2020年湖北部分地区占主导趋势,且其NSP4基因以E2基因型为主要流行形式。展开更多
文摘Background The benefit/risk ratio of stenting in acute ST-segment elevation myocardial infarction （STEMI） patients with single vessel intermediate stenosis culprit lesions merits further study, therefore the subject of the present study. Methods and results It was a pro- spective, multicenter, randomized controlled trial. Between April 2012 and July 2015, 399 acute STEMI patients with single vessel disease and intermediate （40%-70%） stenosis of the culprit lesion before or after aspiration thrombectomy and/or intracoronary tirofiban （15 pg/kg） were enrolled and were randomly assigned （h 1） to stenting group （n = 201） and non-stenting group （n = 198）. In stenting group, patients received pharmacologic therapy plus standard percutaneous coronary intervention （PCI） with stent implantation. In non-stenting group, pa- tients received pharmacologic therapy and PCI （thrombectomy）, but without dilatation or stenting. Primary endpoint was 12-month rate of major adverse cardiac and eerebrovascular events （MACCE）, a composite of cardiac death, non-fatal myocardial infarction （M1）, repeat re- vascularization and stroke. Secondary endpoints were 12-month rates of all cause death, ischemia driven admission and bleeding complica- tion. Median follow-up time was 12.4 ~ 3.1 months. At 12 months, MACCE occurred in 8.0% of the patients in stenting group, as compared with 15.2% in the non-stenting group （adjusted HR： 0.42, 95% Ch 0.19-0.89, P = 0.02）. The stenting group had lower non-fatal MI rate than non-stenting group, （1.5% vs. 5.5%, P = 0.03）. The two groups shared similar cardiac death, repeat revascularization, stroke, all cause death, ischemia driven readmission and bleeding rates at 12 months. Conclusions Stent implantation had better efficacy and safety in reducing MACCE risks among acute STEMI patients with single vessel intermediate stenosis culprit lesions.
文摘目的对人A组轮状病毒进行检测及分离鉴定,并研究其各基因片段的遗传进化关系。方法2019-2020年对湖北武汉市和襄阳市临床腹泻病人的粪便样品进行采集,共319份。设计特异性轮状病毒VP6基因引物,RT-PCR检测轮状病毒的感染情况。将阳性样品接种于MA104细胞进行轮状病毒的分离。RT-PCR特异性扩增VP6基因和特异性间接免疫荧光对其进行病毒鉴定及病毒增殖检测;并进一步通过RT-PCR扩增轮状病毒的11个基因片段,在线工具Rota C V2.0对测序结果进行分型分析。Mega软件对其全基因组序列进行遗传进化分析。结果轮状病毒感染阳性标本共69份,阳性率为21.63%。成功分离获得11株人轮状病毒,主要衣壳蛋白VP7和VP4基因型均为G9P[8]型。其中3株轮状病毒归属于类Wa株毒株,基因型图谱为G9-P[8]-I1-R1-C1-M1-A1-N1-T1-E1-H1。8株毒株在Wa-like的基因型中具有DS-1-like的NSP4为E2基因型特征。基因型图谱为G9-P[8]-I1-R1-C1-M1-A1-N1-T1-E2-H1。结论G9P[8]型人轮状病毒毒株在2019-2020年湖北部分地区占主导趋势,且其NSP4基因以E2基因型为主要流行形式。
